The degree of parasympathetic heart rate control, PC, was defined as the decrease in average heart period (RR interval) caused by the elimination of parasympathetically mediated influences on the heart while keeping sympathetic activity unchanged. By reviewing published results on the interaction of sympathetic and parasympathetic heart rate control, the prediction was made that PC should be directly proportional to VHP, the peak-to-peak variations in heart period caused by spontaneous respiration. In sevel chloralose/urethan-anesthetized dogs the vagi were reversibly blocked by cooling, and PC (the difference between average heart period before and after cooling) and VHP (without cooling) were determined under a variety of conditions that included a) increasing vagal activity by elevating the blood pressure b) sympathetic blockade, and c) parasympathetic blockade. The relationship between VHP and PC was linear with an average correlation coefficient of 0.969 +/- 0.024 (SD) and a PC-axis intercept of 15.2 +/- 25.9 ms. In each dog the correlation coefficient between VHP and PC was higher than between VHP and the average heart period (avg correlation coef: 0.914 +/- 0.044). These results suggest that the degree of respiratory sinus arrhythmia may be used as a noninvasive indicator of the degree of parasympathetic cardiac control.

A simple model to characterize sympathetic and parasympathetic effects on heart rate (R) was tested during rest in 10 nonathletes and 8 world-class oarsmen. The model states that R = mnR0, where R0 is the intrinsic cardiac rate, and m and n depend only on sympathetic and parasympathetic activity, respectively. The multipliers, m and n, were determined by dual pharmacological blockade in two sessions under similar conditions, but in one session propranolol and in the other atropine was given first. In agreement with the model, when corrections were made for atropine-induced blood pressure changes, m and n did not depend on which blocking agent was administered first. In athletes the control heart rate [55 +/- 3.3 (SD) beats/min] and R0 (81 +/- 8.3 beats/min) were lower than in nonathletes (62 +/- 6.0, P less than 0.01 and 102 +/- 11, P less than 0.001, respectively). The sympathetic multiplier, m, was similar (1.18 +/- 0.06 vs. 1.20 +/- 0.05, P greater than 0.4) in the two groups, but n, the parasympathetic multiplier, was closer to 1 in the athletes (0.57 +/- 0.03 vs. 0.51 +/- 0.05, P less than 0.01). We conclude that the model is suitable for the quantitative study of sympathetic/parasympathetic heart rate control in humans, and that the lower resting heart rate in oarsmen is solely due to a reduction in intrinsic cardiac rate, and not to an increase in parasympathetic tone.

No abstract

Cardiac vagal efferent (CVE) activity was recorded from fine strands of the cervical vagus of chloralose-urethane-anesthetized dogs weighing an average of 14.6 kg. In spontaneously breathing animals atropine sulfate in doses of 0.003-1.5 mg significantly increased CVE activity even when the activity was corrected for changes in blood pressure. A 50% average increase (P less than 0.001) in mean activity was observed at a dose of 0.15 mg. The increase was not abolished by vagotomy as long as the animals were allowed to breathe spontaneously. The peripheral effect of atropine was characterized by the relationship between CVE activity and measured heart period changes. A 50% peripheral blockade was achieved at a dose of 0.06 mg; a dose of 1.0 mg produced essentially complete (greater than 90%) blockade. The results quantitatively demonstrate that atropine exerts a powerful central stimulating effect on CVE activity while simultaneously blocking vagal heart rate effects at the periphery.

In conscious dogs the heart rate after atropine is higher than after bilateral vagotomy; we have termed the additional heart rate with atropine "excess tachycardia" (ET). In six dogs the cervical vagosympathetic trunks were exteriorized in skin tubes, and arterial and venous catheters were chronically implanted. Atropine sulfate (0.1 mg/kg iv) injected during cold blockade of the vagi increased the heart rate by only 6 +/- 4 (SE) beats/min (NS) but rewarming the vagi in five of the six dogs after atropine resulted in an additional heart rate increase (ET) of 26 +/- 6 beats/min (P less than 0.005). The ET (41 +/- 11 beats/min) tended to be larger when the animals were pretreated with 1 mg/kg propranolol (P = 0.09). Similar results were obtained when atropine methylbromide, a charged derivative of atropine sulfate, or glycopyrrolate, a synthetic antimuscarinic agent, was substituted for atropine sulfate (ET: 51 +/- 6 and 51 +/- 16 beats/min, respectively). Raising the arterial blood pressure with phenylephrine increased the heart rate further; lowering the blood pressure with sodium nitroprusside attenuated or abolished the ET. Our results show that ET is produced by antimuscarinic agents in general and is not mediated by the beta-adrenergic system. Furthermore, ET is present only when the cervical vagi are intact, probably because ET is mediated by cholinergic vagal efferent fibers via a mechanism that has not yet been recognized in cardiac rate control.